Sorafenib as a Second Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

NCT00595985 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
OTHER
Sponsor class

Stopped low response rate, no evidence of PFS or OS improved.

Conditions

Interventions

Sponsor

Fudan University